![](https://investorshub.advfn.com/uicon/56584.png?cb=1536014904)
Wednesday, June 17, 2020 3:18:29 PM
Meaningful biomarkers
June 2020
by Ilene Schneider
Anavex Life Science
http://ddn-news.com/index.php?newsarticle=14285
NEW YORK—Alzheimer’s disease (AD) is a neurodegenerative process that causes memory loss and other cognitive impairments, gradually destroying an individual's intellect and personality. A progressive, multi-factorial disease, it is the most common cause of primary neurodegenerative dementias. About 5.7 million people in the U.S. have Alzheimer's disease, and about 50 million are stricken worldwide. The current annual cost of dementia is estimated at $1 trillion, a figure expected to double by 2030. There are no treatments for it at this time.
The April 2020 issue of Alzheimer's & Dementia: Translational Research & Clinical Interventions reported on a drug under development by Anavex Life Sciences, a clinical-stage biopharmaceutical company. Anavex seeks to create specific therapies developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases. The article is titled “A precision medicine framework using Artificial Intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the Blarcamesine (ANAVEX2-73) Phase 2a clinical study.”
The drug in question—ANAVEX2-73, also known as blarcamesine—is an orally administered agent that brings back neural cellular homeostasis by acting on Sigma1 and muscarinic receptors, which may stop or reverse Alzheimer’s disease. It also displays anti-convulsant, anti-amnesic, neuroprotective and neurodepressant properties in animal models and holds promise for treating other CNS diseases as well, according to the article.
The journal called this research the first genome-wide effort to find biomarkers in drug responses to AD.
Significant biomarkers found in ANAVEX2-73 were shown to have an important effect on clinical outcomes at one year (57 weeks) and again at more than three years (148 weeks). Researchers believe the study provides a template for the use of big data in precision medicine studies of new therapies for neurological disorders.
The article explained that “Formal concept analysis (FCA) is less affected by population size than other statistical analysis platforms. In this study, FCA, integrated in Knowledge Extraction and Management (KEM) software (v.3.6.2) was used to identify and rank phenotypic and genotypic biomarkers. No link was assumed in these analyses of biomarkers and therapeutic responses, enabling a hypothesis free, data-driven tabulation of all relational effects between potential biomarkers and therapeutic responses in patients with AD.”
According to Dr. Harald Hampel, founding president of the Alzheimer Precision Medicine Initiative (APMI) and lead author of the paper, “This study highlights the relevance of phenotypic and genotypic precision medicine analyses of whole-exome sequencing (WES) and gene expression (RNAseq) data in drug development, and in particular the potential to identify patients’ genetic variants and gene expression changes that may predict increased chances of success of Alzheimer’s disease treatments.”
“We believe that the analysis platform described in this work opens the possibility of using big data-driven, unbiased, genome-wide patient selection marker identification early on in the drug development process of CNS diseases, including Alzheimer’s disease, which is currently applied more routinely in the field of oncology,” added Dr. Christopher U. Missling, president and CEO of Anavex. “Findings from this study were the basis for the testing of potential patient selection markers in our ongoing Phase 2b/3 Alzheimer’s disease (AD) study, as well as the Parkinson’s disease dementia and Rett syndrome studies with ANAVEX2-73 (blarcamesine).”
According to the article, the FCA platform “opens the possibility of using data-driven unbiased biomarker identification early in the drug development process. The white box and systematic approach of FCA is ideal for the analysis of early data, leading to the identification of patient selection biomarkers that can assist in the design of more effective subsequent clinical trials.”
The study was funded by a Michael J. Fox Foundation for Parkinson’s Research grant to Anavex. There will now be a Phase 2b/3 AD study to locate patients with Parkinson’s disease, dementia or Rett syndrome who will benefit from this drug.
Another drug being advanced by the company is ANAVEX3-71, which targets Sigma1 and muscarinic receptors. The compound is a preclinical candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM